Soligenix reports positive long-term follow-up results from its Phase 2 clinical trial of SGX942

Soligenix has announced the long-term follow-up data results from its Phase 2 clinical trial with SGX942 (dusquetide), a first-in-class Innate Defense Regulator (IDR), in the treatment of oral mucositis (OM) in head and neck cancer patients undergoin …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news